Is NVO shooting itself in foot with this new drug? Obesity leads to diabetes. Say NVO sells you the fat pill. You avoid becoming obese and do not develop diabetes. So you have no need for NVO's diabetes drugs. Gain a sale on the fat pill, lose it on the diabetes drugs. What am I missing here?
+! on price, transparency, ease of purchase. But what are the chances management does any of this?
MOre MOney for MO
@@@@@LONDON—Anheuser-Busch InBev NV is talking to banks about financing what could be a roughly £75 billion ($122 billion) deal to buy global beer rival SABMiller SAB.LN +8.68% PLC, according to a person familiar with the matter.
@@@@@A tie-up between the world's two largest brewing companies has been rumored for years, but a revival in global merger activity this year has sparked renewed speculation about a deal. AB InBev isn't in active discussions with SABMiller, said the person, explaining the company is waiting to line up its financing before making a formal approach.
Let them go suck on the KMI lollipop.
@@@@@Goldman Sachs downgraded TransCanada Corporation (NYSE: TRP) from Neutral to Sell with a price target of $47.00. Analyst Theodore Durbin noted high valuation compared to peers. "TRP has outperformed large-cap peers by 12% since the end of 2Q14, partly driven by investor views of break-up potential. Our SOTP suggests this thesis is overdone at current valuation given (1) fundamental headwinds in its core natural gas pipeline business and (2) excessive optimism over its backlog given sub-10% returns on 2/3 of its projects and elevated regulatory and execution risk. TRP shares appear expensive on various metrics after recent outperformance," said Durbin. "We expect TRP to underperform peers due to (1) increasing supply growth from Marcellus/Utica shales which increases volume and tariff risk on TRP’s gas assets (2) relatively weak earnings growth due to its below-average returns on projects (3) recurring execution and volatility issues in its Energy segment and (4) expensive valuation leaving shares vulnerable to negative regulatory or volume developments. Our unchanged 2014 2017 EBITDA estimates are 2-3% above consensus, but our call is more valuation-driven," he added.
Another piece of the puzzle has been solved.
@@@@@LONDON – The German auto parts maker ZF Friedrichshafen said on Monday that it had agreed to sell its stake in a steering systems joint venture to its partner Robert Bosch, further opening the door for a potential takeover of TRW Automotive Holdings, one of the largest auto safety parts makers.
The new LG UHD TV's are listed on a couple of Canadian online retailers.
Bestbuy Canada website has the 77in model
LG 77" 4K Ultra HD 3D Curved OLED Smart TV (77EC9800) - Chrome
Not available online
Reservable in store
$27039.49 + $39.50 Environmental Handling Fee
NCIX Canada website shows both the 65on and 77in models
1LG 65EC9700 65IN 4K 240Hz Smart WiFi WebOS Magic Remote 3D OLED TV (65EC9700) Usually available in 2-5 days
*** $9,997.99 Add this item to your shopping cart now
2LG 77EC9800 77IN 4K 240Hz Smart WiFi WebOS Magic Remote 3D OLED TV (77EC9800) Usually available in 2-5 days
*** $26,997.99 Add this item to your shopping cart now
Duh... I understand it all too well, unlike you it seems. Good companies draw up growth projections and plan fab expansions many months in advance. Ir's unfortunate CREE doesn't seem to be able to do that very well. The opportunity cost of simply 'sitting' on a hoard of cash is unacceptable to most investors.
You post this robo-generated crapola and have the nerve to call others morons? Keep up this nonsense much longer and you'll be on my ignore list.
--- I don't think it's going to fall much further---
Yeah right. There's a big gap to fill way down at the ~35 mark. At that level, and factoring out the 1B in cash, the PEG will be a more reasonable ~1 based on 2015 EPS of 1.85. I'd be looking at that as a level to enter or add to a long position.
Well, they indicated as much when they stated they couldn't fill some short lead-time LED chip orders. So where's the fab expansion announcements? This is a lost opportunity to grow sales.
Also, they stated that high-power is where they feel they achieve highest value-add, so why are they using some of that cash to invest in Lextar for mid-power chips? Why are they not allocating the money exclusively to high-power product development, marketing, and sales? Is it because the end demand growth in that area is just not all that high?
Well, it's about time this happened.
@@@@@The first financial instrument tied to bitcoin has launched following approval from the US government. TeraExchange, a swap execution facility based in Summit, New Jersey, is marketing the bitcoin derivative to large institutions looking for a way to reduce the volatility and risk associated with traditional types of bitcoin exposure. TeraExchange began working on the product earlier this year, and only just received approval from the US Commodities Futures Trading Commission (CFTC), the government agency that regulates futures and options markets. The development of a bitcoin derivative pushes the broader market into uncharted waters, opening the door to move involvement from institutions that, in many cases, are prohibited by their own policies to invest in digital currency.
Cmon now... they're not really hurting much when stock was granted to them at at $0 or options at sub $5.
$25 per patient per day in the pockets of NVO
@@@@5:12 pm Novo Nordisk A/S confirms Saxenda (liraglutide) for the treatment of obesity received positive 14-1 vote in favor of approval from FDA Advisory Committee (NVO) : Co announced that the Endocrinologic and Metabolic Drugs Advisory Committee (:EMDAC) of the FDA has completed its meeting regarding the New Drug Application for Saxenda, the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity